LEVERKUSEN (dpa-AFX) - Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L, BAYRY.PK, BAYZF.PK), Onyx Pharmaceuticals Inc. (ONXX) and Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) reported that a Phase III study evaluating the efficacy and safety of the addition of Tarceva tablets to Nexavar tablets for hepatocellular carcinoma or HCC patients failed in further improvemnt of overall survival, compared with the standard therapy with Nexavar alone.
The SEARCH trial compared Nexavar in combination with Tarceva to Nexavar alone. The safety and tolerability of the treatment combination were generally as anticipated based on experience and use of the two products alone and did not exhibit any new or unexpected toxicities or changes to the respective product safety profiles.
The trial data would be presented at an upcoming scientific meeting. Nexavar is jointly developed by Bayer and Onyx. Nexavar is approved for patients with inoperable liver cancer and advanced kidney cancer.
Copyright RTT News/dpa-AFX